617-04-9

Applied Filters:

Keyword:'617-04-9'

Showing 1-1 of 1 result for "617-04-9" within Papers

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.

Louise Emmett et al.

Clinical genitourinary cancer, 17(1), 15-22 (2018-11-15)

177Lu-PSMA-617 (Lu-PSMA) is an emerging therapy in men with metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential to visually identify phenotypes that will respond to targeted therapy. This study examined the value of 68Ga-HBEDD PSMA-11; prostate-specific membrane antigen

Page 1 of 1